Abstract
Arthritis is one of the most common human ailments worldwide. Arthritis is a
complex family of musculoskeletal disorders with many causes that are not
fully understood. The most crippling of the arthritis family is rheumatoid
arthritis, which is an autoimmune disease. Successful treatment of arthritis
has resulted from a growing array of therapies available to physicians.
While these pharmaceutical products are still used regularly, new
disease-modifying therapies have produced the most impressive results in
treating more severe types of arthritis. Additionally, combination therapies
continue to grow in preference and offer exciting results in disease
management. This Kalorama Information report, The World Market for
Prescription Arthritis Treatments, details the market for these treatments.
The report provides market sizes and forecasts for the following categories of
treatments:
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Biologic Response Modifiers (BRMs) and Immunosuppressants
For each category, the report breaks down the regional market (US, Europe,
Japan, Rest of World), lists major products, and provides market share among
major competitors.
There are several issues and trends that are shaping this market. Some of the
topics, discussed in this report include:
- US Economic Impact of Arthritis
- World Economic Impact of Arthritis
- Obesity and Arthritis
- Trends in Insurance and Reimbursement
- Threat to Anti-TNF Dominance
- ADAM-12 Gene Discovery
- New Pricing Structure in Germany
The information and analysis presented in this report are based on extensive
interviews with senior management of top companies in the worldwide arthritis
treatment market. Background information was obtained from a comprehensive
search of published literature and reports obtained from various government,
business, medical trade, and international journals. Key information from
published literature was used to conduct interviews with over 20 industry
executives and product managers to validate and obtain expert opinion on
current and future trends in the worldwide prescription arthritis treatment
market. Interviews were also used to confirm and/or adjust market size
estimates, as well as in formulating market projections.
The following companies are profiled in the report:
- Abbott Laboratories
- Amgen, Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- Galapagos NV
- Genentech, Inc.
- Horizon Pharma
- Janssen Biotech, Inc
- Novartis International AG
- Pfizer, Inc.
- Roche
- Regeneron
- UCB
All market data pertains to the worldwide market at the manufacturers' level.
Data are expressed in current U.S. dollars. A geographic breakdown is also
included for US, Europe, Japan and Rest of World total market and in each drug
type segment. The base year for data was 2011. Historical data are provided
for each of the years 2009 to 2011, and forecast data are provided for each of
the years 2011 through 2016. Historical, base year, and forecast data are
provided for each market segment. Market shares are provided for each market
segment for the 2011 base year.
All Kalorama Information reports advertise the
single user price, which limits access to one user. We also feature department
and global pricing for reports that will be utilized by more than one user at
your company. Please ask your sales representative or select the correct
license on our website.
For Kalorama's take on the healthcare news of the week, based on our analysis
of healthcare markets, follow Kalorama Information's Key Point Blog at
http://kaloramakeypoint.blogspot.com/
Additional Information
New York, December 5 , 2011-- Led by biologic therapies, the market for
prescription arthritis treatments will exceed $20 billion in 2011, according
to Kalorama Information. The healthcare market research publisher says that
drugs that attack Tumor Necrosis Factor (TNF) led the market to 7.3% growth in
revenues in 2010, and this type of growth is expected to continue, but not
without challenges.
TNF is a type of cell death that leads to inflammation and is a main cause of
arthritis pain. According to the report, products such as Remicade, Enbrel or
Humira that can block TNF have been effective treatments and are leading in
terms of revenue for the treatment of rheumatoid arthritis. Abbott's Humira
leads the group of TNF products, but as the report's author suggests, the
success of these products with rheumatologists and patients also means that it
has become a competitive marketplace.
"Humira will likely become the world's biggest-selling drug by 2016, after the
fall of Lipitor in 2011," said Melissa Elder, the report's author. "However,
new products on the horizon and other factors may challenge this dominance
over the next five years."
Entrants to this area include Bristol-Myers Squibb, with its recent
introduction of Orencia, UCB with Cimzia and many others; so far the existing
products have fended off those challenges. According to the report, some of
the key factors that may challenge the dominance of treatments that attack TNF
include new small molecule therapies that are attempting to vie for first-line
utilization, the launch of biosimilars and physicians gaining comfort with
IL-6 therapies; one or all of these could potentially derail the anti-TNF
dominance.
The report notes that the prescription arthritis market is not without its
challenges for all drug makers. Reimbursement for high-priced biologic
medicines will be challenging over the next few years as payers seek to manage
costs through purchasing arrangements and cost-sharing with their insured
population, which could be a limiter to price growth, according to the report.
Table of Contents
TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Product Market Summary
- Issues and Trends Affecting Market
- Competitor Analysis
CHAPTER TWO: INTRODUCTION
- Overview
- Local Joint Disorder Function
- Etiology and Pathogenesis
- Clinical Manifestations
- Osteoarthritis
- Etiology and Pathogenesis
- Clinical Manifestations
- Treatment
- Infectious Arthritis
- Etiology and Pathogenesis
- Clinical Manifestations
- Systemic Disorders of Joint Function
- Rheumatoid Arthritis
- Etiology and Pathogenesis
- Clinical Manifestations
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Enteropathic Arthritis
- Adult Onset Still Disease
- Juvenile Rheumatoid Arthritis
- Still Disease
- Polyarticular Onset
- World Demographics
CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET
- Product Description
- Market Forecast and Growth
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- Competitive Landscape
CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS
- Product Descriiption
- Sulfasalazine (Azulfidine-Pfizer)
- Gold Compounds
- Penicillamine (Cuprimine-Merck)
- Chloroquine (Aralen-Sanofi-Aventis)
- Methotrexate (Trexall-Duramed; Rheumatrex-DAVA Pharmaceuticals)
- Leflunomide (Arava-Sanofi-Aventis)
- Market Forecast and Growth
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- Competitive Landscape
CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS
- Description
- Tumor Necrosis Factor
- Glucocorticoids
- Azathioprine (Azasan-Salix)
- Adalimumab (Humira-Abbott)
- Anakinra (Kineret-Amgen)
- Basiliximab (Simulect-Novartis)
- Daclizumab (Zenapax-Roche)
- Etanercept (Enbrel-Amgen)
- Infliximab (Remicade-Janssen Biotech)
- Rituximab (Rituxan-Biogen Idec)
- Abatacept (Orencia-Bristol-Myers Squibb)
- Market forecast and Growth
- Markets by Geographical Region
- United States
- Europe
- Japan
- Rest of World
- Competitive Landscape
CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS
- Market Overview
- Product Market Summary
- Product Market Analysis by Geographical Region
- 6 Worldwide Arthritis Treatment Products Competitive Analysis
CHAPTER SEVEN: ARTHRITIS RESEARCH AND DEVELOPMENT TREATMENTS
- Overview
- Duexis
- Gel-One
- ACZ
- Apremilast
- Fostamatinib
- Lodotra
- Stelara
- Tofacitinib
CHAPTER EIGHT: ARTHRITIS TREATMENTS ISSUES AND TRENDS
- Overview
- US Economic Impact of Arthritis
- World Economic Impact of Arthritis
- Obesity and Arthritis
- Trends in Insurance and Reimbursement
- Threat to Anti-TNF Dominance
- ADAM- Gene Discovery
- New Pricing Structure in Germany
CHAPTER SEVEN: CONCLUSIONS
- Conclusion One
- Conclusion Two
- Conclusion Three
- Conclusion Four
- Conclusion Five
CHAPTER EIGHT: COMPANY PROFILES
- Introduction
- Abbott Laboratories
- Amgen, Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- Galapagos NV
- Genentech, Inc.
- Horizon Pharma
- Janssen Biotech, Inc
- Novartis International AG
- Pfizer, Inc.
- Roche
- Regeneron
- UCB
LIST OF COMPANIES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Summary Table: Total World Arthritis Treatment Revenue and Growth Rate by
Drug Type 2011 ($millions)
- Summary Figure:The World Prescription Arthritis Treatments Market Share
Summary 2011
CHAPTER TWO: INTRODUCTION
- Table 2-1: Total Global Population by Selected Geographical Region, 2000 -
2050
- Table 2-2 World Prevalence of Rheumatoid Arthritis by Region
- Figure 2-1:: World Prevalence of Rheumatoid Arthritis, Percent by Region
CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET
- Table 3-1: Select Marketed Non-steroidal Anti-inflammatory Drugs
- Table 3-2 Market Size and Growth for NSAIDs in the Global Arthritis
Treatment Market 2009-2016 ($millions)
- Figure 3-1 Market Size and Growth for NSAIDs in the Global Arthritis
Treatment Market 2009-2016 ($millions)
- Table 3-3: The Worldwide Market for NSAIDs by Geographical Region (US,
Europe, ROW) 2009-2016
- Figure 3-2: The Worldwide Market for NSAIDs Products by Region (US,
Europe, Japan, ROW), 2011
- Figure 3-3: The Worldwide Market for NSAIDs Products by Region (US,
Europe, Japan, ROW), 2016
- Table 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011
- Figure 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011
CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS
- Table 4-1: Selected Prescription Disease Modifying Anti-Rheumatic Drugs
- Table 4-2: Market Size and Growth for DMARDs in the Global Arthritis
Treatment Market 2009-2016 ($millions)
- Figure 4-1: Market Size and Growth for NSAIDs in the Global Arthritis
Treatment Market 2009-2016 ($millions)
CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS
- Table 5-1: Selected Prescription Immunosuppressant and Other Biologic Drugs
- Table 5-2 Market Size and Growth for BMRs and Immunosuppressants in the
Global Arthritis Treatment Market 2009-2016 ($millions)
- Figure 5-1 Market Size and Growth for BRMs and Immunosuppressants in the
Global Arthritis Treatment Market 2009-2016 ($millions)
- Table 5-3: The Worldwide Market for BRMs by Geographical Region (US,
Europe, Japan, ROW) 2009-2016
- Figure 5-2: The Worldwide Market for BRM Products by Region (US, Europe,
Japan, ROW), 2011
- Figure 5-3: The Worldwide Market for BRM Products by Region (US, Europe,
Japan, ROW), 2016
- Table 5-4: The World Biologic Response Modifiers Arthritis Treatment nd
Market Share by Supplier 2011
- Figure 5-4: The Worldwide BRMs and Immunosuppressives Product Market Share
by Supplier 2011
CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS
- Table 6-1: Total World Prescription Arthritis Treatment Revenue and Growth
Rate by Drug Type 2011
- Figure 6-1: The World Prescription Arthritis Treatments Market Share
Summary 2011
- Table 6-3: The World Market for Prescription Arthritis Treatments, by
Geographic Region, 2011
- Figure 6-2: The World Market for Prescription Rheumatoid Arthritis, by
Geographic Region, 2011
